Q-omics provides the consensus-scored DDX19A profile across patient tissues and cancer cell-line models. DDX19A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, DDX19A is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, DDX19A RNA expression shows 20,268 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, HNSC, and ACC as cancer lineages where DDX19A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DDX19A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DDX19A survival associations across molecular data types. DDX19A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DDX19A RNA expression–survival associations across cancer types. High DDX19A expression shows unfavorable associations in BLCA, HNSC and LIHC, but favorable associations in UCS, KIRC and SCLC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for DDX19A RNA expression.
This table summarizes DDX19A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for DDX19A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DDX19A shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, COAD, KIRP and LIHC. The HNSC box plot shows higher DDX19A RNA expression in tumor versus normal tissue (log2 FC = +0.666, t-test p < 0.001).
This table shows molecular features associated with DDX19A in patient tissues and cancer cell lines. In patient samples, DDX19A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DDX19A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
